PCN139 Cost per Consequence Analysis of Erdafinitib and ANTI-PD1/PDL1 Therapies for Metastatic Urothelial Carcinoma FGFR+ from the Perspective of Brazilian Private Health System
2020
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI